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 2 
Abstract 24 
Protein histidine phosphorylation (pHis) is a posttranslational modification involved in 25 
cell cycle regulation, ion channel activity and phagocytosis (1). Using novel 26 
monoclonal antibodies to detect pHis (2), we recently reported that loss of the 27 
histidine phosphatase LHPP results in elevated pHis levels in hepatocellular 28 
carcinoma (3). Here, we show that intestinal inflammation correlates with loss of 29 
LHPP, in DSS-treated mice and in inflammatory bowel disease (IBD) patients. 30 
Increased histidine phosphorylation was observed in intestinal epithelial cells (IECs), 31 
as determined by pHis immunofluorescence staining of colon samples from a colitis 32 
mouse model. However, ablation of Lhpp did not cause increased pHis or promote 33 
intestinal inflammation in physiological conditions or after DSS treatment. Our 34 
observations suggest that increased histidine phosphorylation plays a role in colitis, 35 
but loss of LHPP is not sufficient to increase pHis or to cause inflammation in the 36 
intestine.  37 
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 3 
Introduction  39 
Protein histidine phosphorylation, a poorly characterized posttranslational 40 
modification, refers to the the addition of a phosphate group to the imidazole ring of 41 
histidine via a heat and acid labile phosphoramidate (P-N) bond. Both nitrogens in 42 
the histidine imidazole ring can be phosphorylated resulting in the formation of two 43 
isomers: 1-phosphohistidine (1-pHis) and 3-phosphohistidine (3-pHis). So far, three 44 
mammalian histidine phosphatases (LHPP, PGAM5 and PHPT1) and two histidine 45 
kinases (NME1, NME2) have been described (1). We recently reported that murine 46 
and human hepatocellular carcinomas (HCCs) exhibit elevated histidine 47 
phosphorylation and decreased levels of the histidine phosphatase LHPP. Re-48 
introduction of LHPP resulted in decreased pHis levels in vitro and prevented tumor 49 
formation in an HCC mouse model, suggesting that elevated pHis is pathological (3). 50 
Another recent study showed that LHPP protein expression correlates with survival 51 
of colorectal cancer (CRC) patients, again suggesting that LHPP acts as a tumor 52 
suppressor (4). 53 
Inflammatory bowel disease (IBD) is a major risk factor for CRC (5). IBD is a 54 
general term for intestinal disorders characterized by chronic colitis, such as Crohn’s 55 
disease (CD) and ulcerative colitis (UC). The etiology and the molecular 56 
pathophysiology of IBDs are incompletely understood, resulting in insufficient 57 
progress in the development of novel therapies (6). Importantly, inhibition or deletion 58 
of the K+ channel KCa3.1 prevents colitis progression (7), and PGAM5 inhibits 59 
KCa3.1 by dephosphorylating NME2-pHis118 (8). Taken together, the above 60 
suggests that pHis may play a role in the pathology of IBD. 61 
 62 
Results and Discussion 63 
To investigate if histidine phosphorylation plays a role in colitis, we analyzed a 64 
publicly available transcriptomic profile (E-GEOD-16879) from colon samples of 65 
healthy humans and treatment-naïve IBD patients (9). Patients suffering from CD or 66 
UC showed significantly decreased expression of LHPP, but no difference in 67 
expression of the other known histidine phosphatase genes PGAM5 and PHPT1 68 
(Fig. 1A). Expression of NME1 and NME2 was significantly upregulated in patients 69 
suffering from IBDs (Fig. 1A). Based on these findings, we hypothesized that 70 
elevated pHis, via down-regulation of the histidine phosphatase LHPP and up-71 
regulation of the histidine kinases NME1/2, contributes to disease progression. 72 
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To examine further a role of pHis in IBD, we induced experimental colitis by 73 
treating wild-type mice with dextran sodium sulfate (DSS) (10). Mice exhibited mild 74 
colitis-like symptoms, after 2 to 4 days, that developed into severe colitis with 20% 75 
bodyweight loss and significantly decreased colon length, as observed after one 76 
week of treatment (Fig. 1B). Next, we analyzed expression of known histidine 77 
phosphatases and kinases at different timepoints of DSS treatment. The histidine 78 
phosphatase LHPP, but no other histidine phosphatase, was significantly down-79 
regulated in the colon of wild-type mice after 4 days of DSS treatment, as 80 
determined by immunoblotting (Fig. 1C, D). After one week of treatment, LHPP 81 
expression was further reduced, indicating that LHPP expression negatively 82 
correlated with colitis severity (Fig. 1C, D). Importantly, immunohistochemistry (IHC) 83 
revealed that DSS-dependent down-regulation of LHPP was due mainly to reduced 84 
expression in IECs rather than in infiltrating immune cells (Fig. 1E). Expression of the 85 
histidine kinases was unchanged in DSS-treated mice (Fig. 1C). 86 
We next analyzed histidine phosphorylation in colon samples isolated at 87 
different timepoints of DSS treatment. Immunoblot analysis of colon lysates showed 88 
significantly up-regulated 1- and 3-pHis levels after 7 days of DSS treatment, but not 89 
at earlier timepoints (Fig. 1F-I). In agreement with the IHC results described above, 90 
DSS treatment increased pHis exclusively in IECs, not in infiltrating macrophages 91 
(F4/80-positive cells), as shown by immunofluorescence staining (Fig. 1J). As we 92 
observed down-regulation of LHPP at 4 days of DSS treatment but changes in pHis 93 
only after 7 days, i.e., LHPP loss preceded increased pHis, we speculate that loss of 94 
LHPP contributes to high levels of pHis and disease progression. 95 
 96 
To obtain insight on the role of LHPP in normal development and in colitis 97 
progression, we generated full body LHPP knockout (Lhpp-/-) mice using 98 
CRSPR/Cas9 (see Materials and Methods). Lhpp-/- mice were vital, fertile and 99 
indistinguishable from littermate controls. Histological analysis of the colonic mucosa 100 
did not reveal significant differences between Lhpp-/- and Lhpp+/+ littermates (Fig. 101 
2A). Colons of 1.5-year-old Lhpp-/- mice displayed no sign of cancer and/or 102 
inflammation, and no changes in proliferation or apoptosis (Fig. 2A). Moreover, 103 
immunoblot analysis revealed no significant difference in 1- or 3-pHis levels in large 104 
intestine lysates of Lhpp-/- and Lhpp+/+ littermates (Fig. 2B, C). Colon from Lhpp-/- 105 
mice did not display any differences in PHPT1, NME1 and NME2 protein levels (Fig. 106 
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2B, D), but did exhibit elevated PGAM5 expression, possible as a compensatory 107 
mechanism for loss of LHPP (Fig. 2B).  108 
To determine whether loss of LHPP has an impact on colitis progression, we 109 
treated Lhpp-/- and Lhpp+/+ littermates with DSS. All colitis-related parameters such 110 
as weight loss, colon shrinkage, and elevated spleen weight were similar in Lhpp-/- 111 
and Lhpp+/+ mice, indicating that LHPP loss does not impact colitis development 112 
(Figs. 2E, F). Finally, we did not detect genotype-dependent changes in intestinal 1- 113 
and 3-pHis levels after DSS treatment (Fig. 2G, H), or differences in expression of 114 
known histidine phosphatases or kinases (Fig. 2I).  115 
 116 
In summary, we show that LHPP loss and increased histidine phosphorylation in 117 
intestinal cells correlate with colitis. However, LHPP loss does not appear to be 118 
sufficient for either the observed increase in pHis or inflammation, at least in mice. 119 
Increased NME1/2 expression or activity, which we observed in IBD patients but not 120 
in Lhpp-/- mice, might be required in addition to loss of LHPP. Little is known about 121 
the role of pHis in inflammation. Fuhs et al reported that both malignant epithelial 122 
cells and macrophages show high pHis levels in vitro, and suggested that pHis is 123 
important in phagocytosis (2). As activated macrophages are key players in colitis 124 
(11), we originally expected that the high pHis levels we observed in our 125 
experimental system would be in immune cells. However, results from our IF staining 126 
indicate that DSS treatment triggers pHis in IECs. As we observed high pHis levels 127 
only in late-stage colitis, we cannot exclude that IECs up-regulate pHis as a 128 
response to infiltrating immune cells. Alternatively, upregulated pHis levels in 129 
epithelial cells might promote inflammation by inducing the production of pro-130 
inflammatory signaling molecules and recruitment of macrophages. It remains to be 131 
determined whether increased pHis is a consequence or a cause of inflammation in 132 
IBD. It is also necessary to investigate the role of pHis in the complex interplay 133 
between IECs and immune cells. Finally, it will be important to identify histidine 134 
phosphorylated proteins and to determine their role in inflammatory diseases.  135 
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Materials and Methods 136 
 137 
Mice 138 
To generate Lhpp-/- mice, exon 2 of the mouse Lhpp gene was deleted using 139 
CRISPR/Cas9-mediated non-homologous end joining (NHEJ). Two gRNAs were 140 
designed to target the Lhpp introns 1 (IVS1) and 2 (IVS2). The sequences targeting 141 
the respective introns IVS1-catctgactcacatcatgtgagg and IVS2-142 
gcatcctgaagctagccttgagg were selected for optimal on target activity using the 143 
CRISPOR online tool (12). NHEJ events at the gRNA target sites led to the excision 144 
of the genomic fragment containing exon 2 resulting in a Lhpp-null allele. 145 
CRISPR/Cas9-mediated modification of the Lhpp sequence was carried out by 146 
electroporation of fertilized mouse oocytes as previously described (13). Lhpp-/- and 147 
Lhpp+/+ mice were maintained in a C57BL/6J genetic background. 148 
C57BL/6J wild-type mice were purchased from Janvier Labs. Experimental colitis 149 
was induced in 8- to 12-week-old male mice by administering 2.5% DSS in drinking 150 
water for up to 7 days according to published protocols (10). All animal experiments 151 
conducted were compliant with federal laws and guidelines and were approved by 152 
the veterinary office of Basel-Stadt. 153 
 154 
Histology 155 
Immunohistochemistry (IHC) and H&E stainings were performed as previously 156 
described (14). The following primary antibodies were used: cleaved Caspase 3 157 
(9664; CST), Ki-67 (12202; CST), LHPP (NBP1-83272; Novus). For 158 
Immunofluorescence (IF) stainings, colons were flushed with ice cold PBS (pH 8.5), 159 
cryo-fixed in OCT and stored at -80°C. To prevent heat- and acid-mediated pHis 160 
degradation, all steps during the IF staining process were performed at 4°C and the 161 
pH of all buffers was adjusted to 8.5. After cutting, colon cryo-sections (10μm) were 162 
fixed for 1h in 4% PFA, washed with 1x PBS, blocked for 1h using blocking buffer (1x 163 
PBS, 1% BSA, 0.05% Triton-X 100) and subsequently incubated O/N with primary 164 
antibodies (3-pHis: rabbit, SC44-1 and F4/80: rat, ab6640; abcam) diluted in blocking 165 
buffer. Afterwards, slides were rinsed with PBS and incubated for 1h with secondary 166 
antibodies (Alexa Fluor 488 anti-rabbit and Alexa Fluor 568 anti-rat; Invitrogen) and 167 
DAPI (4083; CST). Finally, the stained sections were washed and mounted with 168 
water-based mounting medium (H-1400; Vector Laboratories).  169 
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 170 
Immunoblotting 171 
Immunoblots were performed and quantified as previously described (3). To detect 172 
pHis, the following monoclonal primary antibodies were used: 1-pHis (0.5ug/ml, SC1-173 
1), 3-pHis (0.5ug/ml, SC44-1). For regular immunoblot analysis the following primary 174 
antibodies were used: Calnexin (ADI-SPA-860; Enzo), LHPP (15759-1-AP; 175 
Proteintech), NME1 (3345; CST), NME2 (ab60602; abcam) PGAM5 (ab126534; 176 
abcam), PHPT1 (LS C192376; LSBio). 177 
 178 
Analysis of publicly available transcriptomic dataset 179 
For mRNA expression analysis the Affymetrix GeneChip Human Genome U133 Plus 180 
2.0 gene expression datasets E-GSE16879 (9) was downloaded from ArrayExpress. 181 
The probes were matched with gene names, using biomaRt R package. Afterwards, 182 
the gene expression levels of LHPP, PGAM5, PHPT1 NME1 and NME2 were 183 
analyzed between different conditions (CTRL, UC, CD). 184 
 185 
Statistical analysis 186 
Data analysis was performed with PRISM 8.0 (GraphPad). Single comparisons were 187 
performed by unpaired, 2-tailed students t-test. Comparison of multiple groups were 188 
performed by one-way ANOVA followed by Tukey’s post hoc test for multiple 189 
comparison. Data are shown as mean±SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 190 
****P < 0.001. 191 
192 
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Figure Legends 202 
Figure 1. Intestinal inflammation correlates with down-regulation of LHPP and 203 
increased histidine phosphorylation. (A) Analysis of publicly available dataset 204 
comparing mRNA expression of known histidine phosphatases (LHPP, PGAM5, 205 
PHPT1) and histidine kinases (NME1/2) in colon tissue from healthy patients (CTRL) 206 
with patients suffering from ulcerative colitis (UC) and Crohn’s disease (CD). (B) 207 
Bodyweight and colon length of mice treated (DSS) and untreated (CTRL) with DSS 208 
at indicated timepoints (days). (C) Immunoblot analysis of histidine phosphatases 209 
and kinases in colon lysates of DSS-treated and -untreated mice at indicated 210 
timepoints. (D) Quantification of LHPP protein levels normalized to Calnexin at 211 
different timepoints of DSS treatment. (E) Immunohistochemistry visualization of 212 
LHPP in colon samples of mice treated (DSS) and untreated (CTRL) for 7 days with 213 
DSS. Scale bar: 100μm. (F-H) Immunoblot analysis of 1- and 3-pHis levels in colon 214 
samples from DSS-treated (DSS) and -untreated (CTRL) mice at indicated 215 
timepoints. (I) Quantification of 1- and 3-pHis levels in H. (J) DAPI and 216 
Immunofluorescence staining of colon samples from untreated (CTRL) and 7-day, 217 
DSS-treated mice. Scale bars: 50μm (low magnification) and 10μm (high 218 
magnification).  219 
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Figure 2. LHPP is dispensable for colitis development. (A) IHC and H&E stainings of 221 
colon samples of 1.5-year-old Lhpp+/+ and Lhpp-/- mice. Red arrowheads indicate 222 
cleaved (cl.) caspase 3 positive cells. Scale bars: 100μm. (B) Immunoblot analysis of 223 
1- and 3-pHis and histidine phosphatase protein levels in colon samples from Lhpp+/+ 224 
and Lhpp-/- mice. (C) Quantification of 1- and 3-pHis levels in B. (D) Immunoblot 225 
analysis of NME1, NME2 and LHPP in colon samples from Lhpp+/+ and Lhpp-/- mice. 226 
(E) Bodyweight during DSS treatment. (F) Colon length and spleen weight after 7 227 
days of DSS treatment. (G) Immunoblot analysis of 1- and 3-pHis and histidine 228 
phosphatase protein levels in colon samples from Lhpp+/+ and Lhpp-/- mice treated 229 
with DSS for 7 days. (H) Quantification of 1- and 3-pHis levels in G with n=6. (I) 230 
Immunoblot analysis of histidine phosphatases and kinases in colon samples Lhpp+/+ 231 
and Lhpp-/- mice treated with DSS for 7 days. 232 
233 
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